The elevation of SOX4 has been reported to be a consequence of miR-129-2 repression in endometrial, gastric, and bladder cancer [17], [18], [51], [52], or as a consequence of miR-335 repression in metastatic breast cancer [50], suggesting the miR-129-2/SOX4 or miR-335/SOX4 regulatory axis as a general strategy for tumor formation or progression. This evidence concerns the gene SOX4 and urinary bladder cancer.